)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Precigen
Precigen (PGEN) investor relations material
Precigen Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
PAPZIMEOS generated $72.9 million in Q3 net product revenue, up 37% QoQ; launch-to-date revenue reached ~$151 million through Q3.
Q3 net income was $35.8 million and operating cash flow was $11.9 million, with positive operating cash flow arriving a quarter ahead of guidance.
Commercial adoption exceeded 500 treatment starts and 300 treatment completions; AdenoVerse received FDA Platform Technology Designation.
Financial highlights
Q3 total revenue was $74.1 million, including $72.9 million of PAPZIMEOS revenue, versus $2.9 million in Q3 2025; 9M revenue was $152.4 million.
Q3 operating income was $38.7 million versus a $34.5 million operating loss in Q3 2025; 9M operating income was $55.3 million versus an $88.8 million operating loss.
Net income was $35.8 million in Q3 and $47.9 million for 9M 2026.
Q3 R&D expense was $6.6 million, down $5.7 million YoY; SG&A was $22.4 million, down $1.6 million YoY.
Q3 gross profit was $67.6 million, with a 91% gross margin; Q3 basic/diluted EPS was $0.10/$0.08.
Outlook and guidance
Management expects continued PAPZIMEOS revenue momentum and spending discipline; no Q4 revenue guidance was given.
U.S. PAPZIMEOS gross margins are expected to stabilize in the high-80% to low-90% range; product costs may rise as a percentage of revenue as pre-launch inventory is depleted.
The redosing study is enrolling, with data anticipated in 2028; pediatric development and geographic expansion are lifecycle priorities, and EMA review is ongoing.
R&D Day is expected to include Phase II PRGN-2009 data in HPV-associated oropharyngeal cancer and a development update.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Precigen
- Q2 2026 profitability reached as PAPZIMEOS revenue soared to $53.1M and adoption accelerated.PGEN
Q2 2026 - All proposals, including board elections and compensation, passed overwhelmingly without shareholder questions.PGENAGM 2026
- Rapidly approved gene therapy for RRP sees strong uptake and expansion into new markets.PGENGoldman Sachs 47th Annual Global Healthcare Conference 2026
- PAPZIMEOS launch drove $21.6M Q1 revenue, rapid adoption, and a sharply narrowed net loss.PGENQ1 2026
- Shareholders will vote on director elections, auditor ratification, executive pay, and a key equity plan amendment.PGENProxy filing
- Virtual meeting to vote on directors, auditor, compensation, and incentive plan amendment.PGENProxy filing
- PAPZIMEOS sets a new standard for RRP, fueling growth and pipeline expansion via a unique platform.PGENFireside chat
- PRGN-2012 pivotal data and cost cuts drive focus as net loss widens and FDA submission nears.PGENQ2 2024
- 51% complete response and 86% surgery reduction achieved, with durable efficacy and strong safety.PGENStudy Result
Next Precigen earnings date
Q4 202625 Mar, 2027
Precigen
Next Precigen earnings date
Q4 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Precigen Inc is an innovator in the discovery and development of next-generation gene and cell therapies, with a mission to enhance the lives of patients through transformational technologies. The company operates in two segments, Precigen, Inc. and Cell Therapy Systems (CTS). The Precigen, Inc. segment discovers and develops the next generation of gene and cellular therapies that address medical needs in cancer, infectious disease and immunological disorders.